HEALIUS News & Analysis

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.

According to our analysts, these three ASX companies lie at very different points on the valuation spectrum.

We recommend participating in the retail offer, providing it is consistent with your financial goals.

Schroders' Australian equity team say investors piling into tech stocks again are ignoring a turning point in markets.

Several high-profile takeover bids for ASX-listed companies currently hang in the balance. We compare three offers on the table, and how to...

The proposed deal to create Australia’s largest pathology provider faces hurdles from the Healius board and regulators, says Morningstar.

Offloading its medical centre and dental business will allow the healthcare company to pay down debt and focus on the turnaround of other units

Star's luck may be turning, while more real estate listings and more GPs suggest things may be on the up for Domain and Healius.

Though Morningstar views the healthcare sectors in both the US and Australia as fairly valued overall, there is a handful of buying opportunities...

Australian hospital operator Healius and equipment provider Fisher and Paykel are among a list of defensive plays that are trading at a discount.